Incretin hormone mimetics and analogues in diabetes therapeutics

Best Practice and Research in Clinical Endocrinology and Metabolism

Volumn 21, Issue 4, 2007, Pages 497-516

  Green, Brian D ^a   Flatt, Peter R ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

exendin; glucagon like peptide 1; glucose homeostasis; glucose dependent insulinotropic polypeptide; incretin; insulin; type 2 diabetes

Indexed keywords

AC 163794; ALBIGLUTIDE; ANTIDIABETIC AGENT; BIM 51077; CJC 1131; CJC 1134 PC; CVX 73; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; INSULIN; JANUS KINASE 1; LIRAGLUTIDE; LY 307161; LY 315902; MEGLITINIDE; METFORMIN; N ACETYL GASTRIC INHIBITORY POLYPEPTIDE; PLACEBO; PROLYL GASTRIC INHIBITORY POLYPEPTIDE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALYL GLUCAGON LIKE PEPTIDE 1; ZP 10A;

CHEMICAL MODIFICATION; CLINICAL TRIAL; DIABETES MELLITUS; DIET THERAPY; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EPIDEMIC; GASTROENTERITIS; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; INJECTION SITE CONTUSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPTIMAL DRUG DOSE; PANCREAS ISLET TRANSPLANTATION; REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MOLECULAR SEQUENCE DATA; PEPTIDES; RECEPTORS, GASTROINTESTINAL HORMONE; VENOMS;

EID: 36548999220     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2007.09.003     Document Type: Review

References (107)

1. Elrick H., Stimmler L., Hlad Jr. C.J., et al. Plasma insulin response to oral and intravenous glucose administration. The Journal of Clinical Endocrinology and Metabolism 24 (1964) 1076-1082
2. Perley M.J., and Kipnis D.M. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. The Journal of Clinical Investigation 46 (1967) 1954-1962
3. Unger R.H., and Eisentraut A.M. Entero-insular axis. Archives of Internal Medicine 123 (1969) 261-266
4. Creutzfeldt M. Candidate hormones of the gut. XV. Insulin-releasing factors of the gastrointestinal mucosa (Incretin). Gastroenterology 67 (1974) 748-750
5. Orskov C., Rabenhoj L., Wettergren A., et al. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43 (1994) 535-539
6. Gallwitz B., Witt M., Morys-Wortmann C., et al. GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1. Regulatory Peptides 63 (1996) 17-22
7. Baggio L.L., and Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007) 2131-2157
8. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
9. Nauck M., Stockmann F., Ebert R., et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29 (1986) 46-52
10. Vilsboll T., Krarup T., Deacon C.F., et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type-2-diabetic patients. Diabetes 50 (2001) 609-613
11. Nauck M.A., Heimesaat M.M., Orskov C., et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. The Journal of Clinical Investigation 91 1 (1993) 301-307
12. Elahi D., McAloon-Dyke M., Fukagawa N.K., et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regulatory Peptides 51 (1994) 63-74
13. Hargrove D.M., Nardone N.A., Persson L.M., et al. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism 44 (1995) 1231-1237
14. Andersen D.K., Elahi D., Brown J.C., et al. Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. The Journal of Clinical Investigation 62 (1978) 152-161
15. Creutzfeldt W.O., Kleine N., Willms B., et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 19 (1996) 580-586
16. Valverde I., Morales M., Clemente F., et al. Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Letters 349 (1994) 313-316
17. Villanueva-Penacarrillo M.L., Alcantara A.I., Clemente F., et al. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 37 (1994) 1163-1166
18. O'Harte F.P., Gray A.M., Abdel-Wahab Y.H., et al. Effects of non-glycated and glycated glucagon-like peptide-1(7-36) amide on glucose metabolism in isolated mouse abdominal muscle. Peptides 18 (1997) 1327-1333
19. Elahi D., Meneilly G.S., Minaker K.L., Rowe J.W., et al. Regulation of hepatic glucose production by gastric inhibitory polypeptide in man. Canadian Journal of Physiology and Pharmacology 65 (1986) 18
20. O'Harte F.P., Abdel-Wahab Y.H., Conlon J.M., et al. Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells. Biochimica et Biophysica Acta 1425 (1998) 319-327
21. Larsson H., Holst J.J., and Ahren B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiologica Scandinavica 160 (1997) 413-422
22. Rudovich N.N., Rochlitz H.J., and Pfeiffer A.F. Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type-2-diabetic patients. Diabetes 53 (2004) 2359-2365
23. Ahren B., Thomaseth K., and Pacini G. Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. Diabetologia 48 (2005) 2140-2146
24. Maxwell V., Shulkes A., Brown J.C., et al. Effect of gastric inhibitory polypeptide on pentagastrin-stimulated acid secretion in man. Digestive Diseases and Sciences 25 (1980) 113-116
25. Chelikani P.K., Haver A.C., and Reidelberger R.D. Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. Ameriacn Journal of Physiology. Regulatory, Integrative and Comparitive Physiology 288 (2005) R1695-R1706
26. Little T.J., Pilichiewicz A.N., Russo A., et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 1916-1923
27. Horowitz M., and Nauck M. To be or not to be - an incretin or enterogastrone?. Gut 55 (2006) 148-150
28. Madsbad S., Schmitz O., Ranstam J., et al. NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type-2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 27 (2004) 1335-1342
29. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type-2 diabetes. Diabetes Care 28 (2005) 1092-1100
30. Zinman B., Hoogwerf B.J., Duran Garcia S., et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type-2 diabetes: a randomized trial. Annals of Internal Medicine 146 (2007) 477-485
31. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type-2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
32. Kim J.G., Baggio L.L., Bridon D.P., et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 52 (2003) 751-759
33. Flint A., Raben A., Rehfeld J.F., et al. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. International Journal of Obesity and Related Metabolic Disorders 24 (2000) 288-298
34. Turton M.D., O'Shea D., Gunn I., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 (1996) 69-72
35. Drucker D.J. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 144 (2003) 5145-5148
36. Buteau J., Foisy S., Joly E., et al. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52 (2003) 124-132
37. 8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. The Journal of Pharmacology and Experimaental Therapeutics 318 (2006) 914-921
38. Stoffers D.A. The development of beta-cell mass: recent progress and potential role of GLP-1. Hormone and Metabolic Research 36 (2004) 811-821
39. Kim S.J., Winter K., Nian C., et al. Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. The Journal of Biological Chemistry 280 (2005) 22297-22307
40. Ehses J.A., Casilla V.R., Doty T., et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 144 (2003) 4433-4445
41. Trumper A., Trumper K., and Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. The Journal of Endocrinology 174 (2002) 233-246
42. Yusta B., Baggio L.L., Estall J.L., et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metabolism 4 (2006) 391-406
43. Couto F.M., Minn A.H., Pise-Masison C.A., et al. Exenatide blocks JAK1-STAT1 in pancreatic beta cells. Metabolism 56 (2007) 915-918
44. Marenah L., McCluskey J.T., Abdel-Wahab Y.H., et al. A stable analogue of glucose-dependent insulinotropic polypeptide, GIP(LysPAL16), enhances functional differentiation of mouse embryonic stem cells into cells expressing islet-specific genes and hormones. Biological Chemistry 387 (2006) 941-947
45. Rickels M.R., Mueller R., Markmann J.F., et al. Effect of GLP-1 on beta- and alpha-cell function during glucose potentiated arginine testing in islet transplant recipients: preliminary results. Diabetes 55 S1 (2006) A60
46. Gorrell M.D. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clinical Science (London) 108 (2005) 277-292
47. Green B.D., Flatt P.R., and Bailey C.J. Inhibition of dipeptidylpeptidase IV activity as a therapy of type-2 diabetes. Expert Opinion on Emerging Drugs 11 (2006) 525-539
48. Deacon C.F. Circulation and degradation of GIP and GLP-1. Hormone and Metabolic Research 36 (2004) 761-765
49. Knudsen L.B., and Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. European Journal of Pharmacology 318 (1996) 429-435
50. Deacon C.F., Plamboeck A., Moller S., et al. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. American Journal of Physiology. Endocrinology and Metabolism 282 (2002) E873-E879
51. Green B.D., Mooney M.H., Gault V.A., et al. Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39). Metabolism 53 (2004) 252-259
52. Deacon C.F., Plamboeck A., Rosenkilde M.M., et al. GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. American Journal of Physiology. Endocrinology and Metabolism 291 (2006) E468-E475
53. Green B.D., Flatt P.R., and Bailey C.J. Dipeptidyl peptidase IV (DPP-4) inhibitors: A newly emerging drug class for the treatment of type-2 diabetes. Diabetes & Vascular Disease Research 3 (2006) 159-165
54. Drucker D.J. The role of gut hormones in glucose homeostasis. The Journal of Clinical Investigation 117 (2007) 24-32
55. Green B.D., Gault V.A., O'Harte F.P.M., et al. Structurally modified analogues of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Current Pharmaceutical Design 10 (2004) 3651-3662
56. O'Harte F.P.M., Gault V.A., Parker J.C., et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia 45 (2002) 1281-1291
57. Gault V.A., Hunter K., Irwin N., et al. Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists. Archives of Biochemistry and Biophysics 461 (2007) 263-274
58. O'Harte F.P.M., Hunter K., Gault V.A., et al. Antagonistic effects of two novel GIP analogues, (Hyp3)GIP and (Hyp3)GIPLys16PAL on the biological actions of GIP and longer term effects in diabetic ob/ob mice. The American Journal of Physiology 292 (2007) E1674-E1682
59. Irwin N., Green B.D., Mooney M., et al. A novel long-acting agonist of glucose-dependent insulinotropic polypeptide (GIP) suitable for once daily administration in type-2 diabetes. The Journal of Pharmacology and Experimental Therapeutics 314 (2005) 1187-1194
60. Holst J.J. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 49 (2006) 253-260
61. Chou J.Z., Place G.D., Waters D.G., et al. A radioimmunoassay for LY315902, an analog of glucagon-like insulinotropic peptide, and its application in the study of canine pharmacokinetics. Journal of Pharmaceutical Sciences 86 (1997) 768-773
62. Rolin B., Larsen M.O., Gotfredsen C.F., et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. American Journal of Physiology. Endocrinology and Metabolism 283 (2002) E745-E752
63. Irwin N., Green B.D., Gault V.A., et al. Degradation, insulin secretion and antihyperglycaemic actions of two palmitate-derivatized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide (GIP). Journal of Medicinal Chemistry 48 (2005) 1244-1250
64. Irwin N., Gault V.A., Green B.D., et al. Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). Biological Chemistry 386 (2005) 679-687
65. Irwin N., O'Harte F.P.M., Gault V.A., et al. Development and characterization of novel long-acting fatty acid derivatised analogs of glucose-dependent insulinotropic polypeptide (GIP) with improved antidiabetic potential. Journal of Medicinal Chemistry 49 (2006) 1047-1054
66. Salhanick A.I., Clairmont K.B., Buckholz T.M., et al. Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulinotropic polypeptide. Bioorganic & Medicinal Chemistry Letters 15 (2005) 4114-4117
67. Lee S., Youn Y.S., Lee S.H., et al. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. Diabetologia 49 (2006) 1608-1611
68. Youn Y.S., Chae S.Y., Lee S., et al. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochemical Pharmacology 73 (2007) 84-93
69. Giannoukakis N. CJC-1131. ConjuChem. Current Opinion in Investigational Drugs 4 (2003) 1245-1249
70. Leger R., Thibaudeau K., Robitaille M., et al. Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog. Bioorganic & Medicinal Chemistry Letters 14 (2004) 4395-4398
71. Baggio L.L., Huang Q., Brown T.J., et al. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53 (2004) 2492-2500
72. Chen D., Liao J., Li N., et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proceedings of the National Academy of Sciences of the United States of America 104 (2007) 943-948
73. Knudsen L.B., Kiel D., Teng M., et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proceedings of the National Academy of Sciences of the United States of America 104 3 (2007 Jan 16) 937-942
74. Pan C.Q., Buxton J.M., Yung S.L., et al. Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. Journal of Biological Chemistry 281 (2006) 12506-12515
75. Claus T.H., Pan C.Q., Buxton J.M., et al. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type-2 diabetes. Journal of Endocrinology 192 (2007) 371-380
76. Fineman M.S., Bicsak T.A., Shen L.Z., et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type-2 diabetes. Diabetes Care 26 (2003) 2370-2377
77. Buse J.B., Henry R.R., Han J., et al. Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type-2 diabetes. Diabetes Care 27 (2004) 2628-2635
78. Degn K.B., Juhl C.B., Sturis J., et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type-2 diabetes. Diabetes 53 (2004) 1187-1194
79. Harder H., Nielsen L., Tu D.T., et al. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type-2 diabetes. Diabetes Care 27 (2004) 1915-1921
80. Nauck M.A., Hompesch M., Filipczak R., et al., NN2211-1499 Study Group. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type-2 diabetes. Experimental and Clinical Endocrinology & Diabetes 114 (2006) 417-423
81. Feinglos M.N., Saad M.F., Pi-Sunyer F.X., et al., Liraglutide Dose-Response Study Group. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type-2 diabetes. Diabetic Medicine 22 (2005) 1016-1023
82. Kapitza C., Trautmann M.E., Heise T., et al. Daily administration of LY307161 SR (GLP-1) analog normalizes blood glucose in type-2 diabetes. Diabetes 51 S2 (2002) A84
83. Gault V.A., Flatt P.R., and O'Harte F.P.M. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential. Neuropeptides 37 (2003) 253-263
84. Meier J.J., Gallwitz B., Kask B., et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type-2 diabetes and healthy control subjects. Diabetes 53 (2004) S220-S224
85. Meier J.J., Nauck M.A., Siepmann N., et al. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection t euglycaemia in first-degree relatives of patients with type-2 diabetes and control subjects. Metabolism 52 (2003) 1579-1585
86. Meneilly G.S., Bryer-Ash M., and Elahi D. The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide. Diabetes Care 16 (1993) 110-114
87. Aaboe K., Knop F.K., Vilsboll T., et al. Acute administration of a sulphonylureas compound restores the insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type-2 diabetes. Diabetologia 50 supplement 1 (2007) S248-S249
88. Hojberg P.V., Vilsboll T., Bache M., et al. Four weeks of near-normalization of blood glucose restores the insulin response to GIP and improves the insulin response to GLP-1 in patients with type-2 diabetes. Diabetologia 50 supplement 1 (2007) S111
89. Lynn F.C., Pamir N., Ng E.H., et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 50 (2001) 1004-1011
90. Gedulin B., Hargrave D., Smith P., et al. Insulinotropic actions of a long-acting GIP analo AC163794 in vivo. Diabetes 56 S1 (2006) A380
91. Yip R.G., and Wolfe M.M. GIP biology and fat metabolism. Life Sciences 66 (2000) 91-103
92. Yamada Y., Miyawaki K., Tsukiyama K., et al. Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes 55 (2006) S86-S91
93. Gault V.A., Irwin N., Green B.D., et al. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalitities of islet structure in obestity-diabetes. Diabetes 54 (2005) 2436-2446
94. Miyawaki K., Yamada Y., Ban N., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nature Medicine 8 (2002) 738-742
95. Hansotia T., Maida A., Flock G., et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight and energy expenditure. The Journal of Clinical Investigation 117 (2007) 143-152
96. Gault V.A., McClean P.L., Cassidy R.C., et al. Chemical GIP receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high fat and cafeteria diets. Diabetologia 50 (2007) 1752-1762
97. Irwin N., McClean P.L., O'Harte F.P.M., et al. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist, (Pro3)GIP, prevents the development of diabetes and related metabolic abnormalities associated with genetically-inherited obesity in ob/ob mice. Diabetologia 50 (2007) 1532-1540
98. Zhou H., Yamada Y., Tsukiyama K., et al. Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action. Biochemical and Biophysical Research Communications 335 (2005) 937-942
99. Gault V.A., O'Harte F.P.M., Harriott P., et al. Characterisation of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochemical and Biophysical Research Communications 290 (2002) 1420-1426
100. Flatt P.R. Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?. Diabetes & Vascular Disease Research 4 (2007) 151-153
101. Clements R.H., Gonzalez Q.H., Long C.I., et al. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type II diabetes mellitus. The American Surgeon 70 (2004) 1-5
102. Guidone C., Manco M., Valera-Mora E., et al. Mechanisms of recovery from type-2 diabetes after malabsorptive bariatric surgery. Diabetes 55 (2006) 2025-2031
103. Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type-2 diabetes. Lancet 368 (2006) 1696-1705
104. Green B.D., Flatt P.R., and Bailey C.J. Development and therapeutic potential of incretin hormone analogues for type-2 diabetes. The British Journal of Diabetes and Vascular Diseases 5 (2005) 134-140
105. Irwin N., Clarke G., Green B.D., et al. Evaluation of the antidiabetic activity of DPP-IV resistant N-terminally-modified versus mid-chain acylated analogues of glucose-dependendent insulinotropic polypeptide. Biochemical Pharmacology 72 (2006) 719-728
106. Vilsboll T., Zdravkovic M., Le-Thi T., et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type-2 diabetes. Diabetes Care 30 (2007) 1608-1610
107. Huang J., Sakamuri S., Leedom T., et al. CVX-73: a GLP-1 mimetic CovX-Body with potent incretin bioactivity and extended pharmacokinetics in rodent and non-human primate. Diabetes 56 S1 (2007) A141